Using 68Ga-TCR-FAPI PET/CT for cancer imaging
Evaluating the Clinical Value of 68Ga-TCR-FAPI PET/CT in Patients With Various Types of Cancer
This study is testing a new type of imaging called 68Ga-TCR-FAPI PET/CT to see if it can better detect cancer in patients who might have tumors.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences Academic / other |
| Locations | 1 site (Beijing) |
| Trial ID | NCT06084767 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of 68Ga-TCR-FAPI PET/CT imaging in patients suspected of having malignant tumors. The study aims to enhance tumor uptake and retention through a targeted radiopharmaceutical approach, which could improve cancer imaging and facilitate targeted therapy. It is an open-labeled, single-arm phase II diagnostic trial that will evaluate PET images and may incorporate other imaging modalities as needed. Additionally, tumor tissue will be collected for histopathological analysis in patients who undergo surgery.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who are suspected to have malignant tumors based on imaging or tumor markers and have a good performance status.
Not a fit: Patients with a history of imaging agent allergies or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve the accuracy of cancer imaging and treatment planning for patients with malignant tumors.
How similar studies have performed: Other studies have shown promising results with similar targeted imaging approaches, indicating potential for success in this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Suspected to have malignant tumors (supported by MRI and/or CT and/or tumor markers and/or pathology report), the tumor may be newly diagnosed or previously treated; * Meet the indications for PET examination, show a clear indication and no contraindications; * Have a performance status of score ≥ 80 on KPS scale or score 0-1 points on ECOG scale, a relatively good general situation; * No major organ dysfunction (heart, lung, liver, kidney and other major organ include), acute or life-threatening status of infection; * Be ≥ 18 years of age; * Be willing and able to understand the research content and provide written informed consent/assent for the trial. Exclusion Criteria: * Have a history of imaging agent allergies; * Does not meet the PET-CT scan sedation requirements, or has contraindications for PET-CT examination; * Be pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial.
Where this trial is running
Beijing
- Peking University Cancer Hospital — Beijing, China (Recruiting)
Study contacts
- Principal investigator: Shaoyan Liu, M.D. — Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Study coordinator: Shaoyan Liu, M.D.
- Email: shaoyanliu.bj@263.net
- Phone: 0086-010-87787190
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.